Atox Bio
Biotechnology, 1000 Park Forty Plaza, Durham, North Carolina, 27713, United States, 11-50 Employees
Phone Number: +19*********
Who is ATOX BIO
Atox Bio is a late stage, critical care immunotherapy company focusing on acute, life threatening, conditions with significant unmet need. The lead candidate in development is Reltecimo...
Read More
-
Headquarters: 1000 Park Forty Plaza, Durham, North Carolina, 27713, United States
-
Date Founded: 2003
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Atox Bio Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Atox Bio
Answer: Atox Bio's headquarters are located at 1000 Park Forty Plaza, Durham, North Carolina, 27713, United States
Answer: Atox Bio's phone number is +19*********
Answer: Atox Bio's official website is https://atoxbio.com
Answer: Atox Bio's revenue is $5 Million to $10 Million
Answer: Atox Bio's SIC: 2836
Answer: Atox Bio's NAICS: 325414
Answer: Atox Bio has 11-50 employees
Answer: Atox Bio is in Biotechnology
Answer: Atox Bio contact info: Phone number: +19********* Website: https://atoxbio.com
Answer: Atox Bio is a late stage, critical care immunotherapy company focusing on acute, life threatening, conditions with significant unmet need. The lead candidate in development is Reltecimod, an immunomodulator, which is designed to enhance the resolution of organ failure in conditions associated with severe acute inflammation such as necrotizing fasciitis (NF) and sepsis. Reltecimod completed enrollment in a phase 3, pivotal trial in patients with Necrotizing Soft Tissue Infections (also known as “flesh eating disease”). This is a life-threatening condition associated with high morbidity and mortality for which no therapy currently exists. In parallel, Reltecimod is also being studied in a phase 3, registrational study in patients with Sepsis Associated Acute Kidney Injury (SA-AKI). Acute kidney injury (AKI) is a common sequela of sepsis in the intensive care unit and the National Kidney Foundation estimates that ~50% of sepsis patients have AKI. This condition is associated with poor prognosis including increased short-term and long-term mortality. To date, no singular effective therapy has been developed to alter the natural history of SA-AKI Reltecimod received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month